Several studies on the association of ACE I/D polymorphism and the risk of developing essential hypertension (EH) [1] [2] [3] have generated inconsistent information. This instigated a search for new polymorphisms in the ACE gene to identify better markers or actual functional variants. Accumulated evidence points to the existence of two QTLs at this chromosomal locus. 4 A genome-scan analysis by The Framingham Heart Study found strong evidence for a QTL on chromosome 17, located close to the ACE gene and linked to blood pressure (BP). 3 Among the 13 polymorphisms of the ACE gene recently reported, a polymorphism in exon 17, ACE 2350 G4A, has the most significant effect on plasma ACE concentrations as it accounts for 19% of the total variance in ACE plasma levels. 5 After adjustment for the effect of ACE 2350 G4A polymorphism, the I/D polymorphism was no longer associated with plasma ACE concentration, indicating that it is in linkage disequilibrium (LD) with ACE 2350 G4A and unlikely to be a functional mutation. 5 We recently found that the ACE 2350 G4A polymorphism is associated with EH. 6 To substantiate our findings further we genotyped our patients 6 for ACE I/D as well using the protocol previously described. 7 Haplotypes of the two ACE polymorphisms were constructed and their segregation with EH was observed. Our study subjects were nationals of the United Arab Emirates (Emirati)-an ethnic group characterized by no alcohol intake and no cigarette smoking and marked by high levels of consanguinity, which raise homozygosity levels and minimize the influence of selection bias and population stratification. Informed consent was taken from all participants and the project was approved by the Research Ethics Committee of the Faculty of Medicine and Health Sciences (UAE University, Al Ain, UAE).
We investigated 245 Emirati unrelated subjects (52% males) with an overall mean age of 56712.4 years and whose clinical characteristics have been previously described, 6 to identify putative associations of the polymorphisms ACE I/D and 2350 G4A with EH. The normotensive (NT) control subjects (N ¼ 131) were age-, gender-and BMImatched with the EH patients (N ¼ 154). The JNC-VI guidelines were followed to determine EH status. 8 Constructing haplotypes of the two polymorphisms increased the heterozygosity index of the marker system from 0.43 and 0.44 for ACE I/D and 2350 G4A polymorphisms respectively, to 0.67 for the haplotypes. Table 1 shows the distribution of ACE I/D and 2350 G4A haplotypes in cases and controls. For the ACE I/D and 2350 G4A polymorphisms, we Zhu et al 5 reported that the ACE 2350 G4A polymorphism was significantly associated with increased plasma ACE levels and systolic blood pressure with an average increase of 3.2 mmHg with each copy of the G2350 allele. We found the I/G haplotype strongly associated with EH and hypothesize that the G2350 allele is involved in increasing susceptibility to EH in the Emirati population. The A2350 allele does not seem to increase an individual's risk of developing EH and it is inherited predominantly in the 'control', NT population. Judging solely from the allele frequencies, it seems that the G2350 allele was first mutated into A2350, and that the I occurred later on a G2350 allele. Therefore, I/G haplotypes occur more frequently among EH subjects and the haplotype is a better marker for EH than G2350 alleles only (mean OR ¼ 7.04, Po0.001).
This study supports the 'RAS hypothesis' of hypertension predisposition and helps to reconcile previous inconsistent findings of several association studies of ACE I/D and EH, demonstrating that the association probably originates from the effects of LD with ACE G4A 2350 polymorphism. This study also demonstrates that constructing more informative markers, such as haplotypes, enhances the visibility of the association of the genetic markers with complex disorders such as EH. Additionally, it implicates the ACE G2350 allele as the functional mutation of the ACE gene responsible for EH through elevated plasma ACE levels.
